KERX Financial Facts

Total research and development: 10.46M
License revenue: 0
See Full Income Statement

Total liabilities and stockholders' equity: -191.95M
Other liabilities: 2K
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 5/8/14 *Est. EPS Growth Rate -133.3% *Last Qtr.
Average EPS % Beat Rate -86.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +6.2% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A +21.3% Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A -9.1% Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A 0% Details
11/2/11 Q311 -$0.15-$0.12 -$0.03N/AN/A N/A +339.9% Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A +238.2% Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A +286.8% Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A +68.5% Details
5/8/12 Q112 -$0.13-$0.12 -$0.01N/AN/A N/A +854.6% Details